Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Depreciation and Depletion (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Depreciation and Depletion for 8 consecutive years, with $5791.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion fell 44.42% year-over-year to $5791.0, compared with a TTM value of $25330.0 through Dec 2025, down 20.9%, and an annual FY2025 reading of $25330.0, down 20.91% over the prior year.
  • Depreciation and Depletion was $5791.0 for Q4 2025 at Abvc Biopharma, down from $5821.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $13305.0 in Q2 2024 and bottomed at $1286.0 in Q1 2024.
  • Average Depreciation and Depletion over 5 years is $6083.8, with a median of $6448.5 recorded in 2022.
  • The sharpest move saw Depreciation and Depletion tumbled 80.19% in 2024, then surged 445.96% in 2025.
  • Year by year, Depreciation and Depletion stood at $3268.0 in 2021, then soared by 96.91% to $6435.0 in 2022, then grew by 17.82% to $7582.0 in 2023, then soared by 37.43% to $10420.0 in 2024, then tumbled by 44.42% to $5791.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for ABVC at $5791.0 in Q4 2025, $5821.0 in Q3 2025, and $6697.0 in Q2 2025.